B-intervention	0	11	Prospective
I-intervention	12	24	surveillance
I-intervention	25	28	and
I-intervention	29	37	targeted
I-intervention	38	51	physiotherapy
O	52	55	for
B-condition	56	59	arm
I-condition	60	69	morbidity
O	70	75	after
O	76	82	breast
O	83	89	cancer
O	90	97	surgery
O	97	98	:
O	99	100	a
O	101	106	pilot
O	107	117	randomized
O	118	128	controlled
O	129	134	trial
O	134	135	.

O	136	138	To
O	139	147	evaluate
O	148	159	prospective
O	160	172	surveillance
O	173	176	and
O	177	185	targeted
O	186	199	physiotherapy
O	200	201	(
O	201	205	PSTP
O	205	206	)
O	207	215	compared
O	216	218	to
B-control	219	228	education
I-control	229	230	(
I-control	230	233	EDU
I-control	233	234	)
O	235	237	on
O	238	241	the
O	242	252	prevalence
O	253	255	of
O	256	259	arm
O	260	269	morbidity
O	270	273	and
O	274	282	describe
O	283	286	the
O	287	297	associated
O	298	305	program
O	306	310	cost
O	310	311	.

O	312	317	Pilot
O	318	328	randomized
O	329	335	single
O	335	336	-
O	336	343	blinded
O	344	354	controlled
O	355	360	trial
O	360	361	.

O	362	367	Urban
O	368	372	with
O	373	384	assessments
O	385	388	and
O	389	398	treatment
O	399	408	delivered
O	409	411	in
O	412	421	hospitals
O	421	422	.

B-eligibility	423	428	Women
I-eligibility	429	438	scheduled
I-eligibility	439	442	for
I-eligibility	443	449	breast
I-eligibility	450	456	cancer
I-eligibility	457	464	surgery
O	464	465	.

O	466	478	Participants
O	479	483	were
O	484	492	randomly
O	493	501	assigned
O	502	503	(
O	503	504	1
O	504	505	:
O	505	506	1
O	506	507	)
O	508	510	to
O	511	515	PSTP
O	516	517	(
O	518	519	n
O	520	521	=
B-intervention-participants	522	524	21
O	524	525	)
O	526	528	or
O	529	532	EDU
O	533	534	(
O	535	536	n
O	537	538	=
B-control-participants	539	541	20
O	541	542	)
O	543	546	and
O	547	555	assessed
O	556	566	presurgery
O	567	570	and
O	571	573	12
O	574	580	months
O	581	592	postsurgery
O	592	593	.

O	594	597	All
O	598	610	participants
O	611	619	received
O	620	625	usual
O	626	630	care
O	630	631	,
O	632	638	namely
O	638	639	,
O	640	652	preoperative
O	653	662	education
O	663	666	and
O	667	676	provision
O	677	679	of
O	680	682	an
O	683	692	education
O	693	700	booklet
O	701	705	with
O	706	718	postsurgical
O	719	728	exercises
O	728	729	.

O	730	733	The
O	734	738	PSTP
O	739	744	group
O	745	748	was
O	749	758	monitored
O	759	762	for
O	763	766	arm
O	767	776	morbidity
O	777	782	every
O	783	788	three
O	789	795	months
O	796	799	and
O	800	808	referred
O	809	812	for
O	813	826	physiotherapy
O	827	829	if
O	830	833	arm
O	834	843	morbidity
O	844	847	was
O	848	858	identified
O	858	859	.

O	860	863	The
O	864	867	EDU
O	868	873	group
O	874	882	received
O	883	888	three
O	889	898	education
O	899	907	sessions
O	908	910	on
O	911	920	nutrition
O	920	921	,
O	922	928	stress
O	929	932	and
O	933	940	fatigue
O	941	951	management
O	951	952	.

O	953	956	Arm
O	957	966	morbidity
O	967	970	was
O	971	976	based
O	977	979	on
O	980	987	changes
O	988	990	in
O	991	994	the
O	995	1003	surgical
O	1004	1007	arm
O	1007	1008	(
O	1008	1009	s
O	1009	1010	)
O	1011	1015	from
O	1016	1026	presurgery
O	1027	1029	in
O	1030	1034	four
O	1035	1042	domains
O	1042	1043	:
O	1044	1045	(
O	1045	1046	1
O	1046	1047	)
O	1048	1056	shoulder
O	1057	1062	range
O	1063	1065	of
O	1066	1072	motion
O	1072	1073	,
O	1074	1075	(
O	1075	1076	2
O	1076	1077	)
O	1078	1086	strength
O	1086	1087	,
O	1088	1089	(
O	1089	1090	3
O	1090	1091	)
O	1092	1098	volume
O	1098	1099	,
O	1100	1103	and
O	1104	1105	(
O	1105	1106	4
O	1106	1107	)
O	1108	1113	upper
O	1114	1118	body
O	1119	1127	function
O	1127	1128	.

O	1129	1136	Complex
O	1137	1140	arm
O	1141	1150	morbidity
O	1151	1160	indicated
O	1161	1162	â‰¥
O	1162	1163	2
O	1164	1171	domains
O	1172	1180	impaired
O	1180	1181	.

O	1182	1188	Second
O	1188	1189	,
O	1190	1193	the
O	1194	1198	cost
O	1199	1201	of
O	1202	1205	the
O	1206	1210	PSTP
O	1211	1218	program
O	1219	1222	was
O	1223	1232	described
O	1232	1233	.

B-outcome	1234	1236	At
I-outcome	1237	1239	12
I-outcome	1240	1246	months
O	1246	1247	,
O	1248	1250	18
O	1251	1252	(
O	1252	1254	49
O	1254	1255	%
O	1255	1256	)
O	1257	1269	participants
O	1270	1271	(
B-iv-bin-abs	1271	1273	10
O	1274	1278	PSTP
O	1279	1282	and
B-cv-bin-abs	1283	1284	8
O	1285	1288	EDU
O	1288	1289	)
O	1290	1293	had
B-outcome	1294	1297	arm
I-outcome	1298	1307	morbidity
O	1307	1308	,
O	1309	1313	with
O	1314	1317	EDU
O	1318	1330	participants
O	1331	1341	presenting
O	1342	1346	more
O	1347	1354	complex
O	1355	1358	arm
O	1359	1368	morbidity
O	1369	1377	compared
O	1378	1380	to
O	1381	1385	PSTP
O	1386	1398	participants
O	1398	1399	.

O	1400	1404	PSTP
O	1405	1417	participants
O	1418	1426	attended
O	1427	1428	4
O	1428	1429	.
O	1429	1430	4
O	1431	1433	of
O	1434	1435	5
O	1436	1447	assessments
O	1448	1452	with
B-iv-bin-percent	1453	1455	90
I-iv-bin-percent	1455	1456	%
B-outcome	1457	1466	retention
O	1466	1467	.

O	1468	1471	The
O	1472	1476	PSTP
B-outcome	1477	1484	program
I-outcome	1485	1489	cost
O	1490	1493	was
O	1494	1495	$
O	1495	1498	150
O	1499	1506	covered
O	1507	1509	by
O	1510	1513	the
O	1514	1520	Health
O	1521	1525	Care
O	1526	1534	Provider
O	1535	1538	and
O	1539	1542	the
O	1543	1550	Patient
O	1551	1554	Out
O	1554	1555	-
O	1555	1557	of
O	1557	1558	-
O	1558	1564	Pocket
O	1565	1571	Travel
O	1572	1576	cost
O	1577	1580	was
O	1581	1584	CAN
O	1584	1585	$
O	1585	1587	40
O	1587	1588	.

O	1589	1592	Our
O	1593	1600	results
O	1601	1608	suggest
O	1609	1613	that
O	1614	1618	PSTP
O	1619	1621	is
O	1622	1630	feasible
O	1631	1636	among
O	1637	1642	women
O	1643	1647	with
O	1648	1654	breast
O	1655	1661	cancer
O	1662	1665	for
O	1666	1671	early
O	1672	1686	identification
O	1687	1689	of
O	1690	1693	arm
O	1694	1703	morbidity
O	1703	1704	.

O	1705	1706	A
O	1707	1713	larger
O	1714	1719	study
O	1720	1722	is
O	1723	1729	needed
O	1730	1732	to
O	1733	1742	determine
O	1743	1746	the
O	1747	1751	cost
O	1752	1755	and
O	1756	1769	effectiveness
O	1770	1778	benefits
O	1778	1779	.
